AEMD NR today .84
Aethlon Medical and Commonwealth Biotechnologies Sign Cooperative Research Agreement
2006-03-29 07:00 ET - News Release
SAN DIEGO -- (Business Wire) -- March 29, 2006
Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in
developing therapeutic devices for infectious disease, announced today
that it has signed a cooperative research agreement with Commonwealth
Biotechnologies, Inc. (CBI). Under the agreement, Aethlon and CBI will
collaborate to pursue federal grant and research opportunities for the
Aethlon Hemopurifier(TM) within biodefense and pandemic preparedness
programs. Since 1999, Commonwealth researchers have managed or
participated in awarded biodefense grants exceeding $20,000,000 in
value. CBI also operates a secure BSL-3 containment facility able to
receive and work with select agents as defined by the Centers for
Disease Control (CDC).
"In addition to its obvious value as a treatment for acute viral
infections, the Hemopurifier(TM) technology developed by Aethlon has
enormous potential as a device to manage exposure to the viral agents
identified by the CDC and other agencies as biothreat agents. It is
simple in concept, straightforward in design, and has been shown to be
effective in removing and trapping a variety of viruses," said Dr.
Richard J. Freer, Chairman & COO of CBI. "We view this partnership as
a natural to bring technology and expertise together to provide a very
strong package for presentation to the many agencies, including the
Department of Homeland Security, concerned with the threat of
bioterrorism," concluded Dr. Freer.
James A. Joyce, Chairman & CEO of Aethlon, stated: "Our colleagues
at Commonwealth have an established record of securing grant income
related to government sponsored biodefense initiatives." Joyce
concluded: "We look forward to leveraging the resources of both
organizations as a means to advance the commercialization of our
Hemopurifier(TM) as a broad-spectrum treatment against evolving
pandemic and bioweapon threats."
About Aethlon Medical
Aethlon Medical is developing the first medical device to treat
infectious disease. The device, known as the Hemopurifier(TM), is a
broad-spectrum treatment countermeasure against drug and vaccine
resistant bioweapons, naturally evolving pandemic threats such as H5N1
Avian Flu, and chronic infectious disease targets including
Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Aethlon
has also initiated research on a second generation Hemopurifier(TM)
that targets the capture of growth factors inherent in the spread of
Cancer. More information on Aethlon Medical and the Hemopurifier(TM)
technology can be found at www.aethlonmedical.com.
About Commonwealth Biotechnologies
Commonwealth Biotechnologies, Inc. is a solutions provider to the
global biotechnology industry, academic institutions, government
agencies, and pharmaceutical companies. It offers broad ranging
expertise and a complete array of the most current analytical and
synthetic chemistries and biophysical analysis technologies, many of
which are not available from other commercial sources. CBI has crafted
a stimulating, open environment where scientists collaborate among
themselves and with its clients, take on interesting challenges and
develop creative solutions. Through its FIL division, CBI offers
comprehensive genetic identity testing, including paternity, forensic,
and CODIS analyses. CBI is accredited by the American Association of
Blood Banks, CLIA, and the National Forensic Science Technology
Council, and operates fully accredited BSL-3 laboratory. For more
information, visit CBI on the web at www.cbi-biotech.com.
Certain of the statements herein may be forward-looking and
involve risks and uncertainties. Such forward-looking statements
involve assumptions, known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or
achievements of Aethlon Medical, Inc to be materially different from
any future results, performance, or achievements expressed or implied
by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the
development of its planned products, the ability of the Company to
obtain FDA and other regulatory approvals permitting the sale of its
products, the Company's ability to manufacture its products and
provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, product liability
exposure, uncertainty of market acceptance, competition, technological
change, and other risk factors. In such instances, actual results
could differ materially as a result of a variety of factors, including
the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and
Exchange Commission filings.
Contacts:
Aethlon Medical, Inc.
Jeff Richardson, 858-459-7800 x302
jrichardson@aethlonmedical.com
or
James A. Joyce, 858-459-7800 x301
jj@aethlonmedical.com
